168 related articles for article (PubMed ID: 36002650)
1. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.
Kiattanaphon A; Vipsoongnern Y; Kunthalert D; Sistayanarain A
Mol Biol Rep; 2022 Oct; 49(10):9437-9443. PubMed ID: 36002650
[TBL] [Abstract][Full Text] [Related]
2. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
3. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan].
Kartashov MY; Svirin KA; Bekbolotov AA; Momusheva KT; Iskanova BM; Solpueva AS; Motorov UT; Narmatova EB; Krivosheina EI; Gladysheva AV; Chub EV; Gashnikova NM
Vopr Virusol; 2023 Jul; 68(3):265-270. PubMed ID: 37436417
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
6. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4AProtease Inhibitors in Iranian HCV/HIV Infected Patients.
Baesi K; Velayati AA; Ashtiani MF; Fakhredini K; Banifazl M; Larijani MS; Basimi P; Ramezani A
Curr HIV Res; 2021; 19(5):391-397. PubMed ID: 34238162
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
[TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
10. Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain.
Ikram S; Ahmad J; Rehman IU; Durdagi S
J Mol Graph Model; 2020 Dec; 101():107727. PubMed ID: 33027738
[TBL] [Abstract][Full Text] [Related]
11. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
[TBL] [Abstract][Full Text] [Related]
12. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
[TBL] [Abstract][Full Text] [Related]
13. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
[TBL] [Abstract][Full Text] [Related]
14. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
[TBL] [Abstract][Full Text] [Related]
16. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors.
Sistayanarain A; Kunthalert D
Arch Microbiol; 2024 Apr; 206(5):215. PubMed ID: 38619622
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
19. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.
Sun D; Dai M; Shen S; Li C; Yan X
Gene Expr; 2018 Mar; 18(1):63-69. PubMed ID: 29221500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
